Answers are grounded in this paper and cite their sources.
Correction report demonstrates the verified clinical indication for ibrutinib in mantle cell lymphoma, highlighting accurate oncology drug approval records.
for an error in the Table . An incorrect indication was given for the drug ibrutinib; the correct indication is mantle cell lymphoma.
No takes yet. Share an insight, caveat, or question.
Mailankody et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: